---
schema_version: "secwatch.filing_event.v1"
accession: "0001411690-25-000036"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:39:11.475605+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bionano Genomics Q4 revenue down 24% YoY to $8.2M; full-year revenue $30.8M, down 15%

## Summary
- Q4 2024 revenue $8.2M vs $10.8M in Q4 2023, decline driven by discontinued clinical services; core product revenue 1% higher for full year.
- GAAP gross margin improved to 42% from 23% YoY; GAAP operating expense cut to $15.4M from $27.4M.
- Full-year product revenue $27.0M (+1% YoY) with consumables +14% and software +11%; instruments down ~$2M.
- Installed OGM systems 371 (+14% YoY); flowcell sales 30,307 (+15% YoY); 336 OGM publications in 2024.
- Cash & securities $20.9M at year-end (incl. $11.4M restricted); raised $10M in Jan 2025 offering; modified debentures to reduce payments.

## SEC filing metadata
- accession: 0001411690-25-000036
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000141169025000036/0001411690-25-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000141169025000036/bngo-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411690-25-000036
- JSON: https://secwatch.observer/filing/0001411690-25-000036.json
- Plain text: https://secwatch.observer/filing/0001411690-25-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.